Adamed acquires 60% of Ecupharma with Advant Nctm and LCA advising

Advant Nctm advised the Adamed Group, while LCA Studio Legale represented the sellers in the transaction. The Adamed Group has acquired a 60% interest in the share capital of Ecupharma, an Italian pharmaceutical company active in the therapeutic areas of neurology, psychiatry, urology and diabetology. The transaction transfers a majority stake in Ecupharma to the Adamed Group. Advant Nctm represented the Adamed Group with a team composed by: partners Lorena Possagno and Jacopo Arnaboldi (team coordinators), managing associate Martina Da Re, and partner Francesco Mazzocchi who handled matters related to the Golden Power regime. LCA Studio Legale represented the sellers with a team composed by: partner Marina Rosito (team coordinator); Giovanni Compagnoni for corporate matters; partner Ranieri Romani with Zuleika Palma, Giulia Maria Bellone and Beatrice Berardinelli for labour matters; and partner Andrea Carreri for Golden Power matters.

Menu

Adamed acquires 60% of Ecupharma with Advant Nctm and LCA advising

Read the full story

Menu

Adamed acquires 60% of Ecupharma with Advant Nctm and LCA advising

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads